MAPT and amyloidosis: To further neuropathologically confirm this current notion in human patients, we compared CSF p-tau181 levels between patients grouped in relation to amyloid-related pathological scores stratified according to tau pathology in a relatively large cohort with various degrees of AD neuropathologic changes.